Document:

EX-10.8

 Exhibit 10.8 

Amendment No. 1 to the 

License Agreement Effective October 15th, 2015 

between Stanford University 
 And

 Epinomics Inc. 
 Effective as of February 1st, 2017, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and
EPINOMICS (“Epinomics”), a company having a primary place of business at 1165A O’Brien Dr, Menlo Park, California 94025, agree as follows: 
  

	1.	 BACKGROUND 

1.        Stanford and Epinomics are parties to a License Agreement effective October 15th, 2015 (“Original Agreement”) covering “ATAC-seq: Fast and efficient chromatin hypersensitivity mapping in small cell numbers using direct transposition” disclosed in Stanford
Docket S12-404. 
 Now, Epinomics has requested and Stanford has agreed to amend the Original Agreement to add an
invention entitled “ATAC-see: a method for integrated imaging and sequencing of the accessible genome” disclosed in Stanford Docket S16-007. 

 

	2.	 AMENDMENT 

  

	2.1	 The first sentence of Paragraph 2.9 of the Original Agreement shall be deleted and replaced with the following
sentence: 

 “2.9 “Licensed Patent” means Stanford’s PCT application Serial Number PCT/US2014/38825
filed May 20, 2014. US patent application Serial Number 62/306,504 filed March 10th, 2016, any foreign patent application corresponding thereto, and any divisional. continuation. or
reexamination application, extension, and each patent that issues or reissues from any of these applications.” 
  

	3.	 OTHER TERMS 

  

	3.1	 All other terms of the Original Agreement remain in full force and effect. 

 

	3.2	 The parties to this document agree that a copy of the original signature (including an electronic copy) may be
used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original
signature. 

 IN WITNESS WHEREOF. the parties hereto have executed this Amendment No. 1 in duplicate originals by
their duly authorized officers or representatives. 
  

			
	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
		
	Signature	 	/s/ Mona Wan
	Name	 	Mona Wan
	Title	 	Associate Director
	Date	 	February 13, 2017

  

			
	EPINOMICS INC.
		
	Signature	 	/s/ Fergus Chan
	Name	 	Fergus Chan
	Title	 	Officer
	Date	 	February 6, 2017EX-10.9

 Exhibit 10.9 

Certain information has been excluded from this exhibit because it (i) is not material and (ii) would be competitively harmful if publicly
disclosed. 
 AMENDMENT No 2 

TO THE 
 LICENSE AGREEMENT
EFFECTIVE THE 15th Day of October 2015 
 BETWEEN 

STANFORD UNIVERSITY 
 AND

 EPINOMICS 
 Effective the 27th day of July 2018, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California,
and 10X GENOMICS INC. (“10X Genomics”), a corporation having a principal place of business at 7068 Koll Center Parkway, Suite 401, Pleasanton, CA 94566, agree as follows: 

 

	1.	 BACKGROUND 

  

	1.1	 Stanford and 10X Genomics are parties to a License Agreement effective October 15th, 2015 (“Original Agreement”) covering “ATAC-seq: Fast and efficient chromatin hypersensitivity mapping in small cell numbers using direct transposition” disclosed in Stanford
Docket S12-404. 

  

	1.2	 The Original Agreement was amended by an Amendment No 1 effective February 1st, 2017 (“Amended Original Agreement”) to add an invention entitled “ATAC-see: a method for integrated imaging and sequencing of the accessible
genome” disclosed in Stanford Docket S16-007. 

  

	1.3	 The Amended Original Agreement was assigned to 10X Genomics on March 7, 2018. 

 

	1.4	 Stanford and 10X Genomics wish to amend the Amended Original Agreement to: 

 

	 	(A)	 Extend the exclusivity term for the Research Field of Use; 

 

	 	(B)	 Add Stanford Docket S17-507 “Simultaneous measurement of RNA
sequence and accessible chromatin sites in single- and ensemble cells”; and 

  

	 	(C)	 Make such other amendments as set forth herein. 

 

	2.	 AMENDMENT 

  

	2.1	 The Background provision of the Amended Original Agreement is hereby deleted in its entirety and replaced with
the following: 

 “Stanford has an assignment of an invention related to mapping chromatin regions, also known as
“Fast and efficient chromatin hypersensitivity mapping in small cell numbers using direct transposition,” invented in the laboratories of Dr. William Greenleaf and Dr. Howard Chang, and described in Stanford Docket S12-404 (the “Invention”). The Invention was made in the course 

 
of research supported by the California Institute of Regenerative Foundation (“CIRM”), The National Institutes of Health (“NIH”), and the Scleroderma Foundation.
Dr. Chang was an employee of The Howard Hughes Medical Institute (“HHMI”) and a Stanford faculty member when the Invention was made. Epinomics assigned this Agreement to 10X Genomics on March 7, 2018. Stanford wants to have the
Invention perfected and marketed as soon as possible so that resulting products may be available for public use and benefit.” 
  

	2.2	 Paragraph 2.9 of the Amended Original Agreement is deleted and replaced in its entirety with the
following paragraph: 

 “2.9 “Licensed Patent” means: 

 

	 	(i)	 Stanford’s PCT application Serial Number PCT/US2014/38825 filed May 20, 2014 (Stanford Docket S12-404), 

  

	 	(ii)	 US patent application Serial Number 62/306,504 filed March
10th, 2016, and PCT application serial number PCT/US2017/021677 (Stanford Docket S16-007), 

 

	 	(iii)	 U.S. provisional patent application number 62/626,603 filed February 5th, 2018, and 

  

	 	(iv)	 any foreign patent application corresponding to either of the foregoing, and any divisional, continuation, or
reexamination application, extension, and each patent that issues or reissues from any of these patent applications. 

 Any
claim of an unexpired Licensed Patent is presumed to be valid unless it has been held to be invalid by a final judgment of a court of competent jurisdiction from which no appeal can be or is taken. “Licensed Patent” excludes any continuation-in-part patent application or patent (each, a “CIP”), and it is agreed that a CIP will only be filed upon mutual consent of the parties.” 

 

	2.3	 Paragraph 3.2 (B) of the Amended Original Agreement is deleted and replaced in its entirety with the
following paragraph: 

 “(B) Exclusivity in the Research Field of Use. The license in Section 3.1 is
Exclusive, including the right to sublicense under Article 4, in the Research Field of Use beginning on the Effective Date and ending on the date of expiration of the Exclusive Term according to Section 3.2 (A) above (the “Research Field
Exclusivity Period”).” 
  

	2.4	 Paragraph 6.1 of the Amended Original Agreement is hereby amended as follows: the last sentence in
Paragraph 6.1 (“If Epinomics fails to meet Milestone 6 set forth on Appendix A, Stanford may, in its sole discretion, convert the license in the Research Field of Use to nonexclusive.”) is deleted in its entirety. 

 

	2.5	 Paragraph 7.6 (A) (2) under “License Maintenance Fee” is deleted and
replaced in its entirety by the following: 

 “7.6 (A) (2) 

[***] 

	2.6	 Paragraph 7.8 “Earned Royalty” is deleted and replaced in its entirety by the following:

 7.8 “Earned Royalty. Epinomics will pay Stanford earned royalties (Y%) on Net Sales as follows: 

[***] 
 By way of an example only,
[***] 
  

	2.7	 Paragraph 7.9 “Combination Product” is modified as follows: the following sentence is added at
the end of Paragraph 7.9: 

 “If, however, the parties determine that the above formula does not adequately and fairly
reflect the contribution of each component in a particular Combination Product(s), then the parties shall negotiate in good faith a modification of the formula for the determination of Net Sales of that Combination Product(s). It is understood by
the parties that kits to perform the ATAC-seq reaction will not be treated as Combination Product, but rather, as a whole Licensed Product.” 
  

	2.8	 Appendix A “Milestones” is deleted and replaced in its entirety by the following:

 “Appendix A — Milestones” 

[***] 
  

	3.	 OTHER TERMS 

  

	3.1	 All other terms of the Amended Original Agreement remain in full force and effect. 

	3.2	 The parties to this document agree that a copy of the original signature (including an electronic copy) may be
used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original
signature. 

 The parties execute this Amendment No 2 by their duly authorized officers or representatives. 

 

			
	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
		
	Signature: 	 	/s/ Mona Wan
	Name:	 	Mona Wan
	Title:	 	Associate Director
	Date:	 	Aug 17, 2018

  

			
	10X GENOMICS, INC.
		
	Signature: 	 	/s/ Eric S. Whitaker
	Name:	 	Eric S. Whitaker
	Title:	 	General Counsel
	Date:	 	August 17, 2018EX-10.13

 Exhibit 10.13 

 
 

 
 Eric S. Whitaker 

Piedmont, CA 
 Dear Eric, 

I am pleased to offer you a position with 10x Genomics, Inc. (the “Company”), as General Counsel based in Pleasanton, California. If you
decide to join us, you will receive a monthly salary of $25,000.00, which will be paid semi-monthly in accordance with the Company’s normal payroll procedures. As a full-time employee, you will also be eligible to receive certain employee
benefits including paid time off, holiday pay, and company sponsored medical insurance. This position reports to the CEO, Serge Saxonov, and will interact closely with colleagues in all disciplines of the company. You should note that the Company
may modify job titles, salaries, and benefits from time to time as it deems necessary. 
 In addition, you are eligible to participate in the 2017 annual
bonus plan. You will receive a separate letter detailing your bonus target and terms of the bonus plan. Full time, non-sales employees hired before August 31st of the bonus plan year are eligible to
participate. Employees must be active 10x employees on the date of payment for any bonus to be earned and paid. Any bonus will be paid at the discretion of the Board of Directors. The Company reserves the right to amend or withdraw the bonus, at its
absolute discretion. 
 Subject to the approval of the Company’s Board of Directors, you will be granted an option to purchase 525,000 shares of the
Company’s common stock. The option will be subject to the terms and conditions applicable to options granted under the Company’s 2012 Stock Plan, as described in that plan and the applicable stock option agreement, which you will be
required to sign. You will vest in 25% of the option shares on the 12-month anniversary of your vesting commencement date and 1/48th of the total option
shares will vest in monthly installments thereafter during continuous service, as described in the applicable stock option agreement. The exercise price per 

  

					
		  	7068 Koll Center Parkway, Suite 401, Pleasanton, CA 94566	  	

 

 
  

 
share will be equal to the fair market value per share on the date the option is granted, as determined by the Company’s Board of Directors in good faith compliance with applicable guidance
in order to avoid having the option be treated as deferred compensation under Section 409A of the Internal Revenue Code of 1986, as amended. There is no guarantee that the Internal Revenue Service will agree with this value. You should consult
with your own tax advisor concerning the tax risks associated with accepting an option to purchase the Company’s common stock. 
 The Company is
excited about your joining and looks forward to a beneficial and productive relationship. Nevertheless, you should be aware that your employment with the Company is for no specified period and constitutes
at-will employment. As a result, you are free to resign at any time, for any reason or for no reason. Similarly, the Company is free to conclude its employment relationship with you at any time, with or
without cause, and with or without notice. We request that, in the event of resignation, you give the Company at least two weeks notice. This at-will employment provision may not be modified or amended except
by a written agreement signed by the CEO of the Company and you. 
 We also ask that, if you have not already done so, you disclose to the Company any and
all agreements relating to your prior employment that may affect your eligibility to be employed by the Company or limit the manner in which you may be employed. It is the Company’s understanding that any such agreements will not prevent you
from performing the duties of your position and you represent that such is the case. Moreover, you agree that, during the term of your employment with the Company, you will not engage in any other employment, occupation, consulting, or other
business activity directly related to the business in which the Company is now involved or becomes involved during the term of your employment, nor will you engage in any other activities that conflict with your obligations to the Company.
Similarly, you agree not to bring any third party confidential information to the Company, including that of your former employer, and that in performing your duties for the Company you will not in any way utilize or disclose any such information.

  

					
		  	7068 Koll Center Parkway, Suite 401, Pleasanton, CA 94566	  	

 

 
  

 The Company is offering you employment because of your experience and personal skills, and not due to your
potential or actual knowledge of a former employer or other persons or entity’s confidential information or intellectual property, including customer lists and trade secrets. Should you accept this offer, we do not want you to retain, make use
of, or share any such information with the Company. Likewise, as an employee of the Company, it is likely that you will become knowledgeable about the Company’s confidential and trade secret information relating to operations, products, and
services. To protect the Company’s interests, your acceptance of this offer and commencement of employment with the Company are contingent upon the execution and delivery to the Company of the Company’s
At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement (“Confidentiality Agreement”) prior to or on your Start Date. The Confidentiality Agreement, which
provides for the arbitration of all disputes arising out of your employment, is enclosed for your review, and you understand that you are being offered employment in exchange for the mutual promise to arbitrate disputes described therein. Because
the Confidentiality Agreement is one of the most important documents you will sign in connection with your employment with the Company, we trust you will review it carefully and let us know if you have any questions. 

The Company reserves the right to conduct background investigations and/or reference checks on all of its potential employees. Your job offer, therefore, is
contingent upon a clearance of such a background investigation and/or reference check, if any. 
 For purposes of federal immigration law, you will be
required to provide to the Company documentary evidence of your identity and eligibility for employment in the United States. Such documentation must be provided to us within three (3) business days of your date of hire, or our employment
relationship with you may be terminated. 
 In addition, please find enclosed a copy of the 10x welcome letter to prospective employees. Read it carefully
and let us know if you any questions. 
 To accept the Company’s offer, please sign and date this letter in the space provided below. If you accept our
offer, your first day of employment will be July 6, 2017. This letter, along with any 

  

					
		  	7068 Koll Center Parkway, Suite 401, Pleasanton, CA 94566	  	

 

 
  

 
agreements relating to proprietary rights between you and the Company, set forth the terms of your employment with the Company and supersede any prior representations or agreements including, but
not limited to, any representations made during your recruitment, interviews, or pre-employment negotiations, whether written or oral. This offer of employment will terminate if it is not accepted, signed, and
returned by June 14, 2017. 
 We look forward to your favorable reply and to working with you at 10x. 

 

	
	Sincerely,
	
	/s/ Serge Saxonov
	Serge Saxonov
	CEO

  

					
		  	7068 Koll Center Parkway, Suite 401, Pleasanton, CA 94566	  	

 

 
  

			
	Agreed to and accepted:
		
	Signature:	 	/s/ Eric S. Whitaker

			
		
	Printed Name:	 	Eric S. Whitaker

			
		
	Date:	 	June 12, 2017

 Enclosures 
  

	 	•	 	 At-Will Employment, Confidential Information, Invention Assignment, and
Arbitration Agreement 

  

	 	•	 	 10x welcome letter to prospective employees 

  

					
		  	7068 Koll Center Parkway, Suite 401, Pleasanton, CA 94566	  	

 July 25, 2017 

Eric Whitaker 
 RE: 10x Genomics Annual Bonus Plan 

Dear Eric, 
 At 10x, investing in our employees is essential.
Without everyone’s contribution, our mission could not be a reality. 
 “We build products that deliver the most complete and
actionable genomics data. We believe in elegant solutions that work every time in everyone’s hands.” 
 In 2017 we announced the 10x Genomics
Annual Bonus Plan. This bonus plan expands the 10x total compensation package which includes your base salary, benefits, and equity. 
 You are receiving
this letter because you are eligible to participate in the Annual Bonus Plan. Your target bonus is 16% of your annual base salary. Your individual bonus amount will be determined using a combination of 100% overall company performance and 0%
individual performance. Bonus amounts will be prorated in the first year of employment and for changes in salary or job level. 
 The company funded pool
can range from 0–125% of target depending on our performance against financial goals we set and were approved by the Board of Directors. Bonuses will be determined and paid early next year. Full time,
non-sales employees hired before August 31st, 2017 of the bonus plan year are eligible to participate. This bonus is being paid as an incentive for continued employment, and therefore employees must be active
10x employees on the date of payment for any bonus to be earned and paid. Any bonus will be paid at the discretion of the Board of Directors. The Company reserves the right to interpret, amend, suspend or terminate the bonus plan or any bonus
payments at its absolute discretion. This bonus plan does not constitute an employment contract. Employment at 10x is at-will. 

We look forward to your ongoing support in finishing the year strong. For additional information on the terms of the plan or a copy of the plan guide, please
contact HR. 
 Best regards, 
 The 10x Executive Team

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]